Professional Organization (Academic Society Activities) :
2019-To date  Secretary of British Viral Hepatitis Group (BVHG)
2016-To date  BASL special interest group (SIG) lead for HBV
2010-To date  Barts Health NHS Trust – Hepatitis B Lead
2011-To date  United Kingdom Advisory Panel for bloodborne viruses
2013-2014     Quality Standard Committee for Chronic Hepatitis B

2011-2013     Member of Advisory Group panel for Chronic Hepatitis B – National Institute of Health and Clinical Excellence

Scientific Activity (Lecture or Editor) :
- Key Opinion Leader and Member of Global Expert Advisory Panels
- European Association for the Study of the Liver: Faculty member
- Invited Chair and Speaker at National & International meetings
- Regular reviewer of grants submitted to the MRC, Rosetree’s Charity
- Editor for Journal of Viral Hepatitis
- Regular reviewer of manuscripts, (Gastroenterology, Gut, Hepatology, Journal of Hepatology)
- Lead for viral liver disease Bart’s Health NHS Trust
- Editorial Board- Journal of Hepatology, Gut and Gastroenterology
- Lead on international Phase 1, 2 and 3 clinical trials in HBV.
- HEFCE Clinical Senior Lectureship

- Hepatology Lead Royal Society of Medicine

Specialty/ Research Field:
RESEARCH THEMES & CAREER CONTRIBUTIONS
- Redefining disease phase in Chronic Hepatitis B (CHB) virus infection
- Use of quantitative HBsAg in disease phase & assessment of CHB
- Age related immune responses in CHB (immune responses in children/young adults)
- Immune responses in CHB therapies
- Biomarkers to determine disease progression in CHB
- Novel tools for disease assessment in CHB
  1. Established a highly successful young adult CHB service; this clinic seamlessly links with our scientific research providing novel insights into the immune defects in young people living with HBV. This has become a flagship service for Barts Health
  2. Produced seminal work on the definition of disease phase and management of CHB in young people, (Kennedy et al. Gastroenterology. 2012, Mason et al., Gastroenterology 2016). This work has also served as a springboard for a broader re-examination of disease in young people and the reassessment of disease phase in international guidelines (EASL 2017).
  3. Investigation of the immune response in evaluating sequential and combination therapies which may be harnessed to improve treatment outcomes in CHB (Gill et al., PLoS Pathog 2016).
  4. Supported the evaluation of using fine needle aspirates to analyse intrahepatic immunity in CHB infection, which will contribute to HBV cure (Gill et al., Gut 2018).
  5. Member of the Guideline Development Group for the NICE guidelines on CHB and subsequent membership of the NICE Quality Standards Committee for the management of CHB in the UK. Expert opinion on the United Kingdom Advisory Panel (UKAP) on blood borne viruses and through this role; I have been asked to undertake a review of the current guidelines on the management of healthcare workers living with HBV and their ability to return to clinical practice. These are highly prestigious roles, which determine healthcare standards and clinical guidance in the UK and will augment future research in hepatitis B